CAJ | 학술논문

近年来，铂类抗肿瘤药物的临床研究进展较快，其抗肿瘤谱广，抗肿瘤活性增强，不良反应降低，已成为目前有关抗肿瘤药物研发的重要领域。新的铂类抗肿瘤药物将从那些在临床研究中显示出低毒性、抗肿瘤谱广、与现有药物无交叉耐药性的化合物中产生。本文就其作用机制、国内外上市开发现状、国内外销售情况及国内研究开发进展等进行综述。
근년래，박류항종류약물적림상연구진전교쾌，기항종류보엄，항종류활성증강，불량반응강저，이성위목전유관항종류약물연발적중요영역。신적박류항종류약물장종나사재림상연구중현시출저독성、항종류보엄、여현유약물무교차내약성적화합물중산생。본문취기작용궤제、국내외상시개발현상、국내외소수정황급국내연구개발진전등진행종술。
In recent years, platinum antitumor drugs in clinical research have rapidly advanced, and they have broad spectrum anti-tumor activity that is progressively enhanced to reduce adverse reactions, which has become the important area of anticancer drug research and development. The new platinum anticancer drugs in clinical studies will be those that show low toxicity, broad spectrum anti-tumor, with no cross-resistance to existing drug compounds. The mechanism, foreign development status, sales and domestic research progress of platinum antitumor drugs are reviewed.